Figure 1.
Patients were randomized into one of two arms, carboplatin, paclitaxel and bevacizumab with or without everolimus (CPB or CPBE). The CPBE arm was amended for excessive toxicity after the first 20 patients.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.